Mesa Laboratories, Inc. MLAB
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 251.32M | 249.73M | 249.13M | 247.54M | 245.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 251.32M | 249.73M | 249.13M | 247.54M | 245.26M |
| Cost of Revenue | 88.43M | 89.38M | 90.86M | 93.06M | 92.82M |
| Gross Profit | 162.89M | 160.34M | 158.27M | 154.48M | 152.44M |
| SG&A Expenses | 116.70M | 117.82M | 119.45M | 117.09M | 117.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 225.18M | 227.25M | 230.62M | 230.31M | 230.22M |
| Operating Income | 26.14M | 22.48M | 18.51M | 17.23M | 15.04M |
| Income Before Tax | 13.39M | 9.36M | 12.01M | 14.07M | 7.26M |
| Income Tax Expenses | 6.73M | 4.56M | 5.30M | 10.33M | 8.83M |
| Earnings from Continuing Operations | 6.67 | 4.80 | 6.71 | 3.73 | -1.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.67M | 4.80M | 6.71M | 3.73M | -1.57M |
| EBIT | 26.14M | 22.48M | 18.51M | 17.23M | 15.04M |
| EBITDA | 48.81M | 45.44M | 41.78M | 42.25M | 39.84M |
| EPS Basic | 1.18 | 0.86 | 1.23 | 0.67 | -0.30 |
| Normalized Basic EPS | 1.49 | 1.05 | 1.37 | 1.60 | 0.83 |
| EPS Diluted | 1.14 | 0.84 | 1.20 | 0.64 | -0.32 |
| Normalized Diluted EPS | 1.46 | 1.03 | 1.35 | 1.58 | 0.81 |
| Average Basic Shares Outstanding | 22.38M | 22.25M | 22.05M | 21.95M | 21.85M |
| Average Diluted Shares Outstanding | 22.63M | 22.40M | 22.20M | 22.09M | 21.96M |
| Dividend Per Share | 0.64 | 0.64 | 0.64 | 0.64 | 0.64 |
| Payout Ratio | 53.26% | 73.63% | 52.49% | 93.97% | -222.26% |